Indomo is developing a device-enabled therapeutic combining the drug candidate DT-001 with the ClearPen™ self-injection system for inflammatory acne. This combination aims to provide patients with a fast-acting, at-home alternative to in-office intralesional corticosteroid injections. The system is designed to allow patients safe, controlled self-administration of proven acne treatment directly at the site of inflammation.
Funding
$17.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with inflammatory acne lesions often require frequent visits to a dermatologist for intralesional triamcinolone acetonide injections. Topical treatments may not be as effective, and in-office procedures can be inconvenient and costly for patients seeking quick resolution of moderate to severe acne.
Solution
Indomo is developing the ClearPen system, a drug-device combination that allows patients to self-administer intralesional injections of triamcinolone acetonide at home for the treatment of inflammatory acne lesions. The ClearPen device is designed to control the dosage, depth, and volume of each injection, replicating the efficacy of in-office procedures. This approach aims to provide patients with convenient access to a clinically recommended treatment, reducing the need for frequent dermatology visits and enabling immediate, on-demand relief.
Target Audience
The primary target audience includes individuals suffering from moderate to severe inflammatory acne lesions who seek a convenient and effective at-home treatment option.
Features
- Intradermal self-injection device designed for at-home use
- Precise dosage, depth, and volume control to replicate in-office injections
- Drug candidate DT-001, for use with the ClearPen device
- Aims to deliver medication directly to the site of inflammation
- Designed to empower patients to safely perform injections at home